Next Article in Journal
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Next Article in Special Issue
Antidepressants and Suicide Risk: A Comprehensive Overview
Previous Article in Journal
Synthesis and Antimicrobial Activity of Some New Quinoxaline Derivatives
Previous Article in Special Issue
Oxytocin and Major Depressive Disorder: Experimental and Clinical Evidence for Links to Aetiology and Possible Treatment
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(8), 2426-2440; doi:10.3390/ph3082426

The Impact of Residual Symptoms in Major Depression

San Francisco VA Medical Center, University of California San Francisco, 4150 Clement Street, 116N, San Francisco, CA 94121, USA
Received: 30 June 2010 / Revised: 2 July 2010 / Accepted: 22 July 2010 / Published: 3 August 2010
(This article belongs to the Special Issue Antidepressants)
View Full-Text   |   Download PDF [166 KB, 5 August 2010; original version 3 August 2010]   |  

Abstract

The current definition of remission from major depressive disorder does not fully take into account all aspects of patient recovery. Residual symptoms of depression are very common in patients who are classified as being in remission. Patients with residual symptoms are at increased risk of functional and interpersonal impairments, and are at high risk for recurrence of depression. This article discusses the incidence of residual symptoms of depression, as well as the risks and consequences of these symptoms, and will review the state of current treatment.
Keywords: major depressive disorder, MDD, antidepressive agents, residual symptoms, depression, depression treatment major depressive disorder, MDD, antidepressive agents, residual symptoms, depression, depression treatment
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Israel, J.A. The Impact of Residual Symptoms in Major Depression. Pharmaceuticals 2010, 3, 2426-2440.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top